Activation of the b 1 -adrenergic receptor and its G protein, G s , induces cardiac hypertrophy. However, activation of classic Ga s effectors, adenylyl cyclases (AC) and protein kinase A, is not sufficient for induction of hypertrophy, which suggests the involvement of additional pathway(s) activated by G s . Recently, we discovered that bg subunits of G q induce phosphorylation of the extracellular regulated kinases 1 and 2 (Erk1/2) at threonine188 and thereby induce hypertrophy. Here we investigated whether b-adrenergic receptors might also induce cardiac hypertrophy via Erk Thr188 phosphorylation.
Methods and results

b-Adrenergic receptor activation induced Erk
Thr188 phosphorylation in mouse hearts and in neonatal cardiomyocytes.
Inhibition of Erk1/2 or overexpression of Erk
Thr188 phosphorylation-deficient mutants (Erk2 T188A and Erk2 T188S ) significantly attenuated b -adrenergic cardiomyocyte hypertrophy in vitro. Erk activity was stimulated by both isoproterenol and the direct AC activator forskolin, but only isoproterenol induced Erk Thr188 phosphorylation.
Erk
Thr188 phosphorylation required Gbg released from G s and was prevented by Gbg inhibition. Similarly, isoproterenol, but not forskolin, induced nuclear accumulation of Erk and cardiomyocyte hypertrophy. Long-term application of isoproterenol in mice caused left ventricular hypertrophy and cardiac remodelling, and this was reduced in Erk2 T188S transgenic mice, supporting the physiological relevance of Erk Thr188 phosphorylation.
Conclusions
Activation of G s by b-adrenergic receptors leads to (i) canonical Erk1/2 activation via AC, and (ii) release of Gbg, which then associates with activated Erk1/2 and induces Erk Thr188 phosphorylation, causing nuclear accumulation
Introduction
Elevated sympathetic activity in heart-failure patients is associated with poor survival. 1, 2 Even though it acutely enhances cardiac contractility, sustained activation of b-adrenergic receptors, particularly of the b 1 subtype, promotes contractile dysfunction, ventricular arrhythmias, and congestive heart failure. 1, 2 The resultant cardiac histology is characterized by cardiomyocyte hypertrophy and concomitant interstitial fibrosis.
2,3
The b 1 -adrenergic receptor (b 1 AR) signals through a stimulatory G protein (G s ) that activates adenylyl cyclase (AC) via the a-subunit (Ga s ) and thereby induces the formation of cAMP and activation of protein kinase A (PKA), the major target of cAMP. PKA phosphorylates several regulatory proteins that are involved in the cardiac contraction-relaxation cycle, such as L-type Ca 2+ channels, phospholamban, troponin I, and ryanodine receptor 2 (RyR 2 ). 2, 4, 5 Interestingly, among mouse models that overexpress components of the b 1 -adrenergic signalling cascade, only mice with cardiac overexpression of b 1 -adrenergic receptors or of Ga s develop a significant degree of cardiac hypertrophy. 6, 7 In contrast, transgenic mouse models that overexpress signalling proteins downstream of G s have little relevance for hypertrophic remodelling. Thus, cardiac overexpression of the predominant cardiac isoforms of AC (AC5 or AC6), overexpression of constitutively active PKA, and knock-in of constitutively phosphorylated RyR 2 all caused no, or only very late, hypertrophic remodelling. 8 -11 These studies suggest that hypertrophic signalling due to b 1 -adrenergic stimulation depends on G protein activation and that direct activation of the pathway downstream of Ga s is not sufficient to induce cardiomyocyte hypertrophy. As cardiac hypertrophy is an important trigger for heart failure, we aimed to clarify the impact of G s activation and the signalling mechanisms involved in b-adrenergically mediated cardiac hypertrophy. In the present study, we give mechanistic insight into the interdependency between Gbg and AC signalling in cardiomyocyte hypertrophy. We demonstrate that b-adrenergically induced cardiac hypertrophy is mediated by direct interaction of G s -derived Gbg subunits with Erk1/2, which triggers an additional autophosphorylation of Erk at threonine 188 (Thr188)-a phosphorylation that mediates hypertrophic Erk1/2 effects. 12 These findings add new insights into the complex mechanisms of b 1 -adrenergic-receptor-mediated adverse remodelling and offer a perspective for new strategies for therapeutic intervention.
Methods
An expanded Methods section including reagents and cDNA constructs is included in the Supplementary material online. Erk2  T188S and Erk2  T188T transgenic mice (T188S and T188T, respectively) were generated as previously described. 12 
Mice and rats
Cell culture and transfection
Neonatal rat cardiomyocytes (NRCMs) were isolated by enzymatic dissociation of left ventricles from 1-or 2-day-old Sprague-Dawley rats as described previously. 12, 13 To isolate left ventricles, neonates were sacrificed by decapitation. Adult mouse cardiomyocytes were isolated from male 8-week-old wild-type or Erk2 T188S transgenic mice as previously described. 12 Briefly, mice were sacrificed by cervical dislocation, and hearts were excised and digested by Langendorff perfusion using a mixture of collagenases A and D (Roche). Cardiomyocytes were transduced by adenoviral infection as indicated. HEK293 and COS7 cells were transfected as described previously with the indicated cDNAs.
12,13
Co-immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblot analyses were performed as described previously. 12 Briefly, cells and left ventricles were lysed in ice-cold NP40 buffer supplemented with phosphatase and protease inhibitors. Dobutamine stimulation of wild-type hearts was achieved by intravenous infusion of dobutamine via the vena jugularis. Isoproterenol hydrochloride was applied continuously as described below.
Analysis of protein synthesis
Protein synthesis rates in NRCMs were measured in the presence of compounds as indicated, and were determined by [ 3 H]isoleucine incorporation. 14 
Fluorescence microscopy
COS7 cells and NRCMs were transfected with the indicated cDNAs, stimulated, and fixed. Nuclei were stained with DAPI. Confocal images were taken with a TCS SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany). YFP was excited at 514 nm and DAPI at 405 nm, and fluorescence images were taken at 550-620 and 425 -460 nm, respectively. Confocal images were recorded using the sequential mode option and analyzed with ImageJ software. For actin staining, NRCMs were fixed after stimulation with isoproterenol (5 mM, 24 h) and stained with Alexa Fluorw488-labelled phalloidin.
Osmotic minipumps
Osmotic minipumps (Alzet, model 1002) were implanted subcutaneously in male 8-week-old wild-type (FVB/N background) and transgenic Erk2 T188T and Erk2 T188S mice. For anaesthesia during surgical implantation of the minipumps, ketamine (150 mg/kg body weight) plus xylazine (0.5 mg/kg) were injected intraperitoneally. The disappearance of the toepinch reflex indicated adequacy of anaesthesia. The implanted pumps continuously released isoproterenol for 14 days (30 mg/g/day).
Echocardiography
Transthoracic echocardiograms were obtained in a blinded manner using the Vevo2100 high-resolution imaging system (VisualSonics, Toronto, Canada) and a 30 MHz probe. Mice were anaesthetized intraperitoneally with pentobarbital (35 mg/kg). Adequacy of anaesthesia was indicated by disappearance of the righting reflex. Values for end-diastolic septal and posterior wall thicknesses and for internal diameters were obtained from two-dimensional M-mode images in the short axis view at the proximal level of the papillary muscles.
Histological analyses
Mouse hearts were fixed and embedded in paraffin. Sections were stained with Sirius Red or haematoxylin and eosin (H&E), and fibrosis and crosssectional areas were quantified as previously described.
12,14
Immunohistochemistry
Histological sections were microwaved in citric acid, blocked with serum, and incubated with anti-phospho-Elk1 antibodies. Primary antibodies were detected using the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA). Nuclei were counterstained with haematoxylin.
Real-time PCR
RNA was extracted from left ventricles using RNeasyw (Qiagen, Hilden, Germany). Total RNA was reverse transcribed using Superscript II reverse transcriptase (Invitrogen/Life Technologies, Darmstadt, Germany). Quantitative real-time PCR was performed using the primers indicated in Supplementary material online.
Statistical analyses
One-way ANOVA followed by a Bonferroni test was used for statistical analyses. Differences with P , 0.05 were considered significant. All data are shown as means + SEM. Confocal, histological, and echocardiographic analyses were performed in a blinded fashion.
Results
b-Adrenergic receptor activation leads to Erk Thr188 phosphorylation
First, we studied whether autophosphorylation of Erk1/2 at Thr188 might occur in response to b-adrenergic receptor stimulation. We analyzed phosphorylation of overexpressed Erk2 and endogenous Figure S1 ). Phosphorylation of the canonical TEY motif is mediated by Mek1/2, the upstream kinases of Erk1/2. This phosphorylation, which correlates with Erk1/2 activity, 15 was also significantly increased in response to short-to medium-term Iso exposure ( Figure 1A -C and Supplementary material online, Figure S1 ), but this was not evident in wild-type mice after 14 days of Iso treatment ( Figure 1D ). This may be due to the rather oscillating nature of canonical Erk1/2 phosphorylation.
12
The extent of b-adrenergically induced Erk Thr188 phosphorylation was similar to that of other hypertrophic stimuli that activate G q -coupled receptors and thereby induce Erk Thr188 phosphorylation, such as phenylephrine ( Figure 1A ) and angiotensin II ( Figure 1B ).
12,16 -18
Taken together, these data show that activation of b-adrenergic receptors induces phosphorylation of Erk1/2 at Thr188.
Isoproterenol-induced cardiomyocyte hypertrophy is mediated by Erk
Thr188 phosphorylation
To confirm that Erk1/2 are involved in Iso-induced cardiomyocyte hypertrophy, 19 Figure 2D ). In addition, confocal images of phalloidin-stained NRCMs showed that Iso-induced cytoskeletal reorganization was less pronounced in NRCMs overexpressing phosphorylation-deficient mutants, Erk2 T188S or Erk2 T188A , than in Erk2 T188T -overexpressing cells (Supplementary material online, Figure S2C ). Of note, Erk2 T188T -overexpressing NRCMs showed hypertrophic responses similar to cells infected with a control virus (Supplementary material online, Figure S2D and S2E). Similar results were obtained in isolated adult cardiomyocytes: unlike wild-type YFP-Erk2 (T188T), overexpression of YFP-Erk2 T188A significantly reduced b-adrenergically induced cardiomyocyte hypertrophy ( Figure 2E and Supplementary material online, Figure S2F ). Together, these data show that b-adrenergically induced cardiomyocyte hypertrophy involves Erk1/2 and that Erk Thr188 phosphorylation is essential in this signalling pathway.
G s (Ga and Gbg) activation is necessary for Erk Thr188 phosphorylation
To exclude the involvement of G proteins other than G s , we then analyzed whether Iso-induced Erk1/2 activation and cardiomyocyte hypertrophy is indeed induced by G s . To inhibit G q signalling, we overexpressed RGS2 (regulator of G protein signalling 2), which is an efficient G q inhibitor. 20 While RGS2 suppressed G q -mediated b-adrenergically induced cardiac hypertrophy hypertrophic signals in response to phenylephrine ( Figure 3A) , it did not affect Iso-induced cardiomyocyte hypertrophy ( Figure 3B ). Furthermore, RGS2 overexpression did not attenuate Iso-stimulated Erk1/2 activity ( Figure 3C and Supplementary material online, Figure  S3A and S3B). Participation of G i signalling in b-adrenergically mediated Erk1/2 activation was excluded by treatment of the cells with pertussis toxin (PTX) ( Figure 3D and Supplementary material online, Figure S3C and S3D). 21 To examine the involvement of G s in b-adrenergically induced hypertrophy, we analyzed the effects of inhibition and activation of the Ga s effector AC. Inhibition of AC with KH7 reduced the cardiomyocyte hypertrophic response to isoproterenol ( Figure 3E and Supplementary material online, Figure S3E ).
In contrast, forskolin, a direct activator of AC, 22, 23 did not induce cardiomyocyte hypertrophy at concentrations up to 30 mM ( Figure 3F and data not shown), even though Erk1/2 activation in response to Iso or forskolin treatment was comparable (Supplementary material online, Figure S3F ). These results suggest that Ga s induced AC activation is not sufficient to induce cardiomyocyte hypertrophy upon b-adrenergic receptor activation, indicating that Gbg might be involved. Co-immunoprecipitation assays of Gbg subunits with Flag-tagged Erk2 in HEK293 cells ( Figure 3G ) and in NRCMs ( Figure 3H) , as well as endogenous Erk1/2 in NRCMs ( Figure 3I) , showed that Iso stimulation led to a significant increase in co-immunoprecipitated Gbg b-adrenergically induced cardiac hypertrophy ( Figure 3G -I) . The detected association of Gbg and Erk in response to Iso implies an involvement of Gbg in the hypertrophic signalling pathway of Erk1/2. In line with this hypothesis, direct activation of AC by forskolin was not sufficient to induce the Gbg-mediated and hypertrophic Erk Thr188 phosphorylation ( Figure 3J ). Experiments with HEK293 cells overexpressing the Gbg inhibitory C-terminus of the b-adrenergic receptor kinase (bARK-ct) further delineated the importance of the co-incidence of Ga s and Gbg activation for the induction of Erk Thr188 phosphorylation. While bARK -ct did not affect Erk2 activation, it clearly inhibited Erk2 Thr188 phosphorylation
(Supplementary material online, Figure S3G ). Taken together, our results suggest that G s -derived Gbg subunits interact directly with Erk1/2, activated by signals downstream of AC, to cause Erk Thr188 phosphorylation, which is required for cardiac hypertrophy. In contrast, activation of the cAMP pathway alone (by forskolin) lacks the Gbg-dependent effect on Erk1/2 and is not sufficient to induce cardiac hypertrophy.
Loss of Erk Thr188 phosphorylation decreases cardiac hypertrophy in vivo
We then investigated the role of Erk Thr188 phosphorylation in b-adrenergically mediated hypertrophy in vivo. For this study, we used wild-type FVB/N mice and transgenic mice overexpressing wildtype Erk2 (T188T) or Erk2 T188S (T188S). Erk2 overexpression levels are shown in Supplementary material online, Figure S4 . Since we had not observed significant differences between Erk2 T188A and Erk2 T188S in the in vitro studies (see Figure 2C and D), we used only Erk2 T188S transgenic mice for this in vivo analysis. For b-adrenergic stimulation, mice were subjected to isoproterenol applied by osmotic mini-pumps for 14 days. Echocardiographic analyses and histology were performed to phenotype mice before and after isoproterenol treatment. In the absence of isoproterenol there were no differences in morphology or heart function between different genotypes ( Figure 4 and Supplementary material online, Figures S5  and S6 ). Furthermore, consistent with earlier reports, cardiac function was not impaired at this time-point (Supplementary material online, Figure S5B -E).
-26
In FVB/N wild-type (WT) mice and in mice overexpressing Erk2 (Erk2 T188T ), isoproterenol significantly increased left ventricular hypertrophy to a comparable extent, as shown by increases in septal and posterior wall thickness ( Figure 4A and Supplementary material online, Figure S5A ), left ventricular weight ( Figure 4B and Supplementary material online, Figure S5F ), and cardiomyocyte size ( Figure 4C and Supplementary material online, Figure S6A ). In line with previous reports, wild-type Erk2 had no effect on the development of cardiac hypertrophy. 12, 27 In contrast, phosphorylation-deficient Figure S6B and 6C). Iso-induced hypertrophy was accompanied by interstitial fibrosis (quantified in histological sections by Sirius Red staining; Supplementary material online, Figure S6D and SE) and elevated heart-failure markers [collagenase 3 and atrial natriuretic factor (ANF)] 28,29 in
WT and Erk2 T188T transgenic mice. All these pathological changes were markedly less pronounced in Erk2 T188S transgenic mice ( Figure 4D-F) . Taken together, our data show that mutation of Thr188 in Erk2 inhibits cardiac hypertrophy and remodelling in vivo, and thus reveal a key role of Erk Thr188 phosphorylation in b-adrenergic-receptor-mediated cardiac hypertrophy.
Thr188-phosphorylated Erk accumulates in the nucleus
To investigate the downstream effects of Erk Thr188 phosphorylation in b-adrenergic signalling, we analyzed phosphorylation of Elk1, a nuclear Erk1/2 target involved in cardiac hypertrophy. 30, 31 Western blot analysis revealed a significant increase of Elk1 phosphorylation in hearts from mice overexpressing Erk2 T188T after 14 days of Iso treatment.
This increase in Elk1 phosphorylation was almost absent in Erk2 T188S transgenic mice ( Figure 5A ), suggesting that Erk Thr188 phosphorylation is required for phosphorylation of this nuclear Erk target. Phospho-Elk1 was also detected in response to Iso treatment in the cardiomyocyte nuclei of heart sections from Erk2
T188T , but not from Erk2 T188S , transgenic mice ( Figure 5B ). Confocal microscopy analysis of the subcellular distributions of YFP-tagged Erk2 T188T and Erk2 T188A in COS7 cells (Supplementary material online, Figure S7A and S7B), in NRCMs ( Figure 5C ), or isolated adult cardiomyocytes ( Figure 2E ) further showed that phosphorylation-deficient Erk2 T188A -in contrast to WT Erk2-did not accumulate in the nucleus in response to Iso stimulation. In line with these findings, YFPtagged Erk2 T188T also did not accumulate in the nucleus after activation by forskolin, which does not induce Erk Thr188 phosphorylation ( Figure 5D ). These experiments suggest that nuclear accumulation of Erk is impaired in the absence of Erk Thr188 phosphorylation and that retention of Erk in the cytosol may inhibit phosphorylation of nuclear targets known to mediate hypertrophy.
Discussion
Transgenic animal studies with constitutive overexpression of b-adrenergic receptors as well as studies of reverse remodelling using b-blocking agents have revealed that the b 1 -adrenergic receptor subtype is the major mediator of pathological hypertrophy and that it is associated with a marked increase in interstitial fibrosis and heart failure. 2, 4, 5 However, signalling pathways involved in b-adrenergically induced hypertrophy are not well understood. As mentioned above, classic b-adrenergic signalling involves activation of G s , followed by stimulation of ACs, increases in cAMP, and enhanced activity of PKA. However, distinct phenotypes obtained in mice with cardiac overexpression of the different components of the b-adrenergic signalling pathway suggest that hypertrophy is not (or not alone) mediated via this classic pathway. In line with these reports, our experiments showed that direct stimulation of AC with forskolin does not foster the induction of cardiomyocyte hypertrophy ( Figure 3F ). Taken together, these observations give rise to the hypothesis that an additional pathway branches off at the level of G s and that this is important for the induction of cardiac hypertrophy.
In our study, we show that direct interaction of G s -derived Gbg subunits with Erk1/2 may represent this additional pathway ( Figure 6 ). Erk1/2 are classically activated by receptor tyrosine kinases, such as growth factor receptors, but also by G protein coupled receptors, and play key roles in cardiac hypertrophy and remodelling. 15 Erk Thr188 phosphorylation was shown to be triggered by the association of G q -derived Gbg subunits with activated Erk1/2. In addition, dimerization of Erk was shown to be a prerequisite for Gbg binding to the activated kinases. Erk phosphorylated at Thr188 accumulated in the nucleus and ultimately resulted in Erk-mediated hypertrophy. 12, 36 Our data show that b-adrenergic receptor activation indeed induces direct interaction of Erk1/2 with G s -derived Gbg subunits ( Figure 3G -I ) as well as Erk Thr188 phosphorylation (Figure 1 and Supplementary material online, Figure S1 ). Using phosphorylationdeficient mutants of Erk2 (Erk2  T188A and Erk2  T188S ) , we demonstrated the impact of Erk Thr188 phosphorylation on cardiomyocyte hypertrophy in vitro and in vivo in response to b-adrenergic receptor b-adrenergically induced cardiac hypertrophy activation ( Figures 2 and 4) . These phosphorylation-deficient mutants seem to display a dominant-negative effect on cardiac hypertrophy by sequestering activated Erk within the cytosol. The dominant-negative effect can be mediated via sequestration of activated Erk1 and/or Erk2, since Erk2 can form dimers, (homodimers, 12, 36 but also heterodimers with Erk1) (data not shown). In line with this hypothesis, our localization studies in COS7 cells (Supplementary material online, Figure S7 ) and in NRCMs ( Figure 5C and D) show that the phosphorylation-deficient mutants are retained in the cytosol. The finding that forskolin did not cause nuclear localization of Erk2 even suggests that Erk Thr188 phosphorylation may be mandatory for nuclear Erk localization ( Figure 5D ). Sequestration of Erk is most likely mediated via dimerization, as it has been shown that Erk2
T188S
can efficiently dimerize with activated WT Erk2 in HEK293 cells.
12
Analysis of the activation of Elk1 (a prototypical nuclear target of Erk) in our mouse experiments showed that activation of Elk1 is indeed attenuated in the presence of phosphorylation-deficient Erk2 T188S ( Figure 5A and B) . However, the mechanisms of nuclear accumulation of Erk after Erk Thr188 phosphorylation are still unclear.
These may involve preferential transport of Erk Thr188 -phosphorylated Erk into the nucleus, as has been shown for TEY-phosphorylated Erk; 37 in contrast, phosphorylation at the TEY motif does not always correlate well with nuclear accumulation of Erk, 38 raising the possibility of additional determinants. 39 Taken together, these Figure S3G ). Thus, Gbg subunits seem to be needed for the induction of Erk Thr188 phosphorylation but not for activation of Erk
Our experiments thus suggest that induction of hypertrophy via b-adrenergic receptors depends on two pathways: canonical Erk1/2 activation (most likely by activation of signals downstream of AC), and Gbg release from G s . These pathways combine to produce Erk Thr188 phosphorylation as the decisive output to hypertrophic gene expression ( Figure 6 ). The elucidated mechanism of b-adrenergically induced hypertrophy helps to explain the apparent differences in the hypertrophic phenotypes of transgenic mice overexpressing different components of the b-adrenergic signalling pathway.
It remains to be elucidated whether Erk Thr188 phosphorylation also mediates b-adrenergic cardiac hypertrophy by regulating other pathways that have been implicated in b-adrenergically mediated cardiomyocyte hypertrophy. Since we have shown here that Erk Thr188 phosphorylation induces Elk1 phosphorylation, and since we have also previously shown that mitogen-and stress-activated protein kinase-1 (MSK1) and c-Myc become hyperphosphorylated, 12 these effects of Thr188-phosphorylated Erk on transcription factors may promote an increase of the expression of exchange factors activated by cAMP (Epac) and Ca 2+ /calmodulin dependent protein kinase II (CamK II). The latter are two examples of proteins with upregulated expression levels in heart failure and with known involvement in b-adrenergically induced cardiac hypertrophy. 40 -45 Cardiac hypertrophy is an important trigger for arrhythmias and heart failure.
1,2 The mechanism described here specifically elucidates the hypertrophic mechanism and accompanied remodelling as part of the pathological signalling of b-adrenergic receptors. Since functional deterioration of the heart was not observed in our experimental model, in line with similar observations by others, it could not be assessed whether blockage of Erk Thr188 phosphorylation can rescue heart failure induced by chronic stimulation of b-adrenergic receptors. However, the observed reduction of interstitial fibrosis and ANF expression support the hypothesis that reduction of cardiac hypertrophy by overexpression of phosphorylation-deficient Erk2 T188S will be protective for the heart. Interference with Erk Thr188 phosphorylation may even be of particular therapeutic interest in b-adrenergically induced hypertrophy, since studies that targeted Erk1/2 more unspecifically (by inhibiting Erk1/2 activity or by genetic deletion) showed enhanced pathological remodelling. 46 -48 Future studies will be needed to evaluate the impact of Erk Thr188 phosphorylation on b-adrenergically induced heart failure. Taken together, our results show that Erk Thr188 phosphorylation strongly participates in cardiac hypertrophy mediated by b-adrenergic receptor activation and that this effect depends on a complex activation mechanism involving activation of both Erk1/2 and G proteins. The complexity of this pathway in eliciting cardiac hypertrophy in response to chronic stimulation of b-adrenergic receptors raises the hope that it might provide multiple sites for eventual pharmacological intervention.
Supplementary material
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